Trial Profile
Phase II study of irinotecan and tegafur gimeracil for NSCLC with EGFR mutation which resistant to EGFR-TKI
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Aug 2022
Price :
$35
*
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary) ; Irinotecan (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 16 Aug 2022 Results published in the Medical Oncology
- 30 Mar 2013 New trial record